Pharmacokinetics of an orally administered methylcellulose formulation of gallium maltolate in neonatal foals.

This research article critically evaluates the pharmacokinetics of gallium maltolate, a semi-metal used for its anti-microbial impacts, administered orally to neonatal foals. The prime focus of the study is to analyze its preventive and therapeutic effects against Rhodococcus equi pneumonia in foals.

Pharmacokinetics Study

• The research conducted a pharmacokinetics study with neonatal foals. The research involved two batches of six foals each. One batch was administered with 20 mg/kg of gallium maltolate, while the second batch received 40 mg/kg.
• Serial serum samples were collected from the foals and the serum gallium concentrations were ascertained using inductively coupled plasma mass spectroscopy.
• The study observed a rapid absorption of gallium, with a T(max) of 4 hours. Moreover, it detected a mean C(max) of 0.90 or 1.8 microg/mL in foals that received 20 or 40 mg/kg respectively.

Variability in Results

• Though rapid absorption of gallium was seen, substantial variability was noticed in C(max) among the foals. Only half of the foals receiving 20 mg/kg reached serum concentrations of >0.7 microg/mL, implying a wide variance in the therapeutic impact of the given dose.
• The elimination half-life also varied from 32.8 to 32.4 hours depending on the dosage received, adding to the inconsistent therapeutic results among the foals.

Future Considerations

• Based on the varied results, the researchers suggest that future studies should consider a dose of at least 30 mg/kg orally every 24 hours for optimal pharmacodynamic study and efficacy results.
• This recommendation has been made in light of the therapeutic level suggested against Rhodococcus equi by prior studies, which establishes an important baseline for future research.